| Document |
Document Title |
|
WO/2023/149827A1 |
The present invention refers to a process for production of di-trimethylolpropane oxetane, wherein trimethylolpropane oxetane, dimethyl carbonate and a catalyst (base) are reacted in an aqueous solution.
|
|
WO/2023/147673A1 |
The present disclosure generally relates to a combination therapy comprising an anti- clusterin antibody or antigen binding fragment thereof and a taxane and its use in the treatment of subjects having non-small cell lung cancer (NSCLC)....
|
|
WO/2023/141705A1 |
The present disclosure relates to the treatment of prostate cancer using a combination of cepharanthine or a pharmaceutically acceptable salt thereof, and a taxane, optionally paclitaxel, docetaxel, or cabazitaxel. Also described herein ...
|
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
|
WO/2023/109563A1 |
The present invention relates to a cabazitaxel prodrug anti-tumor preparation, designs and synthesizes a cabazitaxel-fatty alcohol small molecule prodrug containing different fatty alcohol side chains and different connecting chains of g...
|
|
WO/2023/100830A1 |
The present invention provides a new polymer from which a cured object having a high refractive index can be produced. The polymer according to the present invention is represented by general formula (1). (In the formula, X1 represents a...
|
|
WO/2023/096111A1 |
The present application relates to a novel quinizarine derivative, wherein the quinizarine derivative has a bromodomain extra-terminal (BET) protein inhibition ability, and thus can be used in a pharmaceutical composition for preventing ...
|
|
WO/2023/089522A1 |
Disclosed herein are compounds of Formula (I), Formula (III) or Formula (IIIa), or pharmaceutically acceptable salts thereof, wherein A, L, X1, X2, a, b, R1 and R2 are as defined herein. Also disclosed are lipid nanoparticles comprising ...
|
|
WO/2023/072671A1 |
The present invention relates to the use of strobilurin type compounds of formula I and the N- oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b...
|
|
WO/2023/065434A1 |
Provided in the present invention is a preparation method for oxetane-2-methylamine, which belongs to the technical field of organic synthesis. In the present invention, [2-(1-ethoxyethoxy)methyl]propylene oxide is used as an initial raw...
|
|
WO/2023/053054A1 |
Disclosed is a process for the preparation of taxanes esterified with octadecanedioic acid which comprises reacting a taxane with an octadecanedioic acid protected in one of the two carboxyl groups and protected with a group removable by...
|
|
WO/2023/054626A1 |
Provided is a cyclopropanamide derivative. A compound represented by formula (1) [wherein: n represents an integer of 0, 1, 2 or 3; ring A represents (1) 4-pyridyl which may be substituted with 1 to 4 substituents, or (2) phenyl which is...
|
|
WO/2023/045909A1 |
The present application discloses small molecule compounds having a naphthylamine structure and an application thereof. In the present application, the structure of a compound having a structure as shown in general formula (I) is as show...
|
|
WO/2023/045910A1 |
The present application discloses a small-molecule compound having a naphthol ether structure, and a use thereof. Disclosed in the present application are a compound having a structure represented by general formula (I), a pharmaceutical...
|
|
WO/2023/032820A1 |
Provided are: a resin composition including at least one resin selected from the group consisting of cyclized resins and precursors thereof, and a compound B, which has a ring opening-polymerizable group, also has at least one structure ...
|
|
WO/2023/017269A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein RA and RB are as defined herein.
|
|
WO/2023/014907A1 |
Described herein, inter alia, are LPAR1 antagonists and uses thereof.
|
|
WO/2023/007188A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or pol...
|
|
WO/2023/007408A1 |
The present invention discloses 4-substituted arylamidine compounds of formula (I), wherein, R1, R2, R3, R4, R4a, R5, A and D are as defined in the detailed description. The present invention further discloses methods for their preparati...
|
|
WO/2023/000636A1 |
A method for synthesis of (3-fluorooxetan-3-yl)methyl 4-methylbenzenesulfonate. A target product is prepared by using diethyl 2-fluoromalonate as a raw material and by means of a methylolation reaction, a hydroxyl protection reaction, a ...
|
|
WO/2023/283594A1 |
A composition, comprising: a metal carbonyl anion; and a cation ionically bonded to the metal carbonyl anion. The cation includes a ligand and a metal centered compound. The ligand includes two residues of 3,5-substituted salicylaldehyde...
|
|
WO/2022/269251A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein RA, RB, RC and RD are as defined herein.
|
|
WO/2022/267989A1 |
The present invention relates to a eugenol bio-based silicon-containing oxetane monomer, a method for preparing the monomer, a photocurable composition containing the monomer, and a photocurable material prepared from the photocurable co...
|
|
WO/2022/248944A1 |
A multifunctional copolymeric nanoparticle, including a plurality of 1,4-diazabicyclo[2.2.2]octane (DABCO) monomers crosslinked with a plurality of bromoacetyl cystamine (BBAC) monomers. Also, each of the plurality of DABCO monomers and ...
|
|
WO/2022/227556A1 |
The present application relates to a docetaxel-fatty alcohol small molecule prodrug and construction of self-assembled nanoparticles thereof, in particular to a docetaxel-fatty alcohol small molecule prodrug having tumor reduction respon...
|
|
WO/2022/227555A1 |
The present invention relates to a cabazitaxel-fatty alcohol prodrug and the construction of a self-assembled nanoparticle thereof, and specifically relates to a disulfide bond-bridged redox dual-sensitive cabazitaxel-fatty alcohol prodr...
|
|
WO/2022/226623A1 |
The present disclosure generally relates to a method for allowing intra-tumor immune infiltration and/or for treating a subject having cancer. The method of the present disclosure is based on the administration of an anti-clusterin antib...
|
|
WO/2022/226641A1 |
The present disclosure generally relates to a method of treating cancer by administration of autologous tumor infiltrating lymphocytes (TILs) isolated from a subject that has received prior treatment with an anti-cancer therapy that comp...
|
|
WO/2022/227554A1 |
The synthesis of a larotaxel-fatty alcohol small molecule prodrug with a tumor reduction response characteristic and the construction of a self-assembling nanoparticle, and the use thereof in the preparation of a drug delivery system. Pr...
|
|
WO/2022/226637A1 |
The present disclosure generally relates to a method for treating a subject having cancer. The method of the present disclosure allows infiltration of immune cells into the tumor microenvironment and may be used to modulate an antitumor ...
|
|
WO/2022/226156A1 |
Provided according to embodiments of the invention are methods of forming a lipstatin derivative, (S)-1-((2S,3S)-3-ethyl-4-oxooxetan-2-yl) tridecan-2-yl formyl-L-alaninate. Such methods include one or more reaction steps that include the...
|
|
WO/2022/221086A1 |
A continuous method of carbonylating an epoxide and/or lactone with carbon monoxide with improved catalyst efficiency and reactor productivity is comprised of reacting the epoxy and/or lactone in a solvent with carbon monoxide in the pre...
|
|
WO/2022/210324A1 |
Provided are: a resin composition including a precursor of a cyclized resin and a base generator, wherein the base generated by the base generator is a base that cyclizes within the same molecule and becomes a tertiary amine, and the bas...
|
|
WO/2022/187957A1 |
The present document describes methods for improving likelihood of survival in a stage III-IV ovarian cancer patient, and the use of chemotherapeutic agents (paclitaxel and carboplatin) and therapeutic monoclonal antibodies (oregovomab a...
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/187010A1 |
Disclosed herein is a method including decoupling one or more polymers containing the residue of a propiolactone, an epoxide, or both from a metal centered compound in a composition to form a Lewis acid containing one or more polar ligan...
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/038365A9 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.
|
|
WO/2022/133027A1 |
Compounds of formula (1) wherein R1 represents a -C(R2)(R3)-[C(R4)(R5)]m-L-R6 group or -R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment o...
|
|
WO/2022/130352A1 |
Present invention relates to compounds of general formula (I), their tautomeric forms, stereoisomers, pharmaceutically acceptable salts and pharmaceutical composition containing them. Invention also relates to process for the preparation...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/120353A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/112351A1 |
The present invention relates to malonamide compounds of the formula (I) wherein the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of sai...
|
|
WO/2022/090723A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA1, RA2, R1 to R5, L and RB are as defined herein.
|
|
WO/2022/091045A2 |
|
|
WO/2022/063071A1 |
Provided in the present invention are a novel inhibitor simultaneously targeting PTL and NPC1L1 and the use thereof. Namely, provided are a compound having a structure as represented by formula (I) and the use thereof in the preparation ...
|
|
WO/2022/022448A1 |
The present invention belongs to the pharmaceutical field. Specifically, the present invention relates to a neuraminidase inhibitor compound as represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, or a ...
|
|
WO/2022/018594A1 |
This invention relates novel intermediates used for the synthesis of substituted 3,4-dihydroisoquinolinone compounds which are EZH2 inhibitors and the synthesis of said intermediates.
|
|
WO/2021/252607A1 |
Functionalized beta-propiolactone in which one or more of the carbons or the ring structure are substituted with either hydrogen or a hydrocarbyl moiety which may contain heteroatoms and substituents.
|
|
WO/2021/243415A1 |
Provided herein is dendrimer-targeting agent conjugate comprising: (a) a dendrimer comprising i) a core unit (C); and ii) building units (BU), wherein the dendrimer has from two to six generations of building units; and wherein the core ...
|
